Edition:
United Kingdom

Transgene SA (TRNG.PA)

TRNG.PA on Paris Stock Exchange

2.94EUR
4:35pm BST
Change (% chg)

€-0.07 (-2.33%)
Prev Close
€3.01
Open
€3.00
Day's High
€3.00
Day's Low
€2.90
Volume
46,553
Avg. Vol
42,423
52-wk High
€3.38
52-wk Low
€2.57

About

Transgene SA is a biopharmaceutical company. The Company designs and develops immunotherapy products to treat cancer and infectious diseases. These products use viral vectors to directly or indirectly destroy diseased cells. The Company has approximately three products in clinical development: two immunotherapy products for... (more)

Overall

Beta: -0.15
Market Cap(Mil.): €186.79
Shares Outstanding(Mil.): 56.43
Dividend: --
Yield (%): --

Financials

  TRNG.PA Industry Sector
P/E (TTM): -- 69.30 32.55
EPS (TTM): -0.50 -- --
ROI: -39.20 8.91 13.82
ROE: -143.68 10.05 15.24

AstraZeneca ties up with France's Transgene to develop viral immunotherapies

British drugmaker AstraZeneca Plc and French biopharmaceutical firm Transgene SA entered into an agreement on Thursday to co-develop five cancer-killing viral immunotherapies.

02 May 2019

AstraZeneca ties up with France's Transgene to develop viral immunotherapies

British drugmaker AstraZeneca Plc and French biopharmaceutical firm Transgene SA entered into an agreement on Thursday to co-develop five cancer-killing viral immunotherapies.

02 May 2019

AstraZeneca ties up with France's Transgene to develop viral immunotherapies

May 2 British drugmaker AstraZeneca Plc and French biopharmaceutical firm Transgene SA entered into an agreement on Thursday to co-develop five cancer-killing viral immunotherapies.

02 May 2019

Earnings vs. Estimates